Sage Journals: Discover world-class research

Abstract

Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease, and an effective vaccine is not available. In this study, we compared the immunogenicity and protection efficacy of recombinant proteins corresponding to different domains of the SARS-coronavirus spike protein. Trimeric recombinant proteins were created by fusing the foldon domain derived from T4 bacteriophage to the carboxy-termini of individual domains of the spike protein. While the full-length ectodomain (S) of the spike protein, the full-length ectodomain fused to foldon (S-foldon), the S1 domain (S1), S1-foldon, and the S2 domain(S2) antigens all elicited comparable antibody titers as measured by ELISA, S-foldon induced a significantly higher titer of neutralizing antibody and S2 protein did not elicit virus neutralizing antibodies. When tested in a mouse virus replication model, all the mice vaccinated with the S1, S1-foldon, S, or S-foldon were completely protected.

Get full access to this article

View all access options for this article.

References

Enjuanes

, Dediego

, Alvarez

, Deming

, Sheahan

, Baric

. Vaccine to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res, 2008; 133:45–62.

Roper

, Rehm

. SARS vaccines: Where are we? Expert Rev Vaccines, 2009; 8:887–898.

Marra

, Jones

, Astell

et al. The genome sequence of the SARS-associated coronavirus. Science, 2003; 300:1399–1404.

Rota

, Oberste

, Monroe

et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science, 2003; 300:1394–1399.

Hofmann

, Pöhlmann

. Cellular entry of the SARS coronavirus. Trends Microbiol, 2004; 12:466–472.

, He

, Zhou

, Liu

, Zheng

, Jiang

. The spike protein of SARS-CoV. A target for vaccine and therapeutic development. Nat Rev Microbiol, 2009; 226–236.

Song

, Seo

, Stadler

et al. Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol, 2004; 78:10328–10335.

Tao

, Strelkov

, Mesyanzhinov

, Rossmann

. Structure of bacteriophage T4 fibritin: A segmented coiled coil and the role of the C-terminal domain. Structure, 1997; 5:789–798.

Yang

, Kong

, Huang

et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature, 2004; 428:561–564.

10.

Ksiazek

, Erdman

, Goldsmith

et al. and SARS Working Group. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med, 2003; 348:1953–1966.

11.

Reed

, Muench

. A simple method of estimating fifty percent endpoints. Am J Hyg, 1938; 27:493–497.

12.

Kam

, Kien

, Roberts

et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine, 2007; 25:729–740.

13.

Zhou

, Post

, Chubet

et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine, 2006; 24:3624–3631.

14.

Kammerer

, Mechling

, Schulthess

et al. Stabilization of short collagen-like triple helices by protein engineering. J Mol Biol, 2001; 308:1081–1089.

15.

Roberts

, Lamirande

, Vogel

et al. Animal models and vaccines for SARS-CoV infection. Virus Res, 2008; 133:20–32.

16.

Keng

, Zhang

, Shen

et al. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents. J Virol, 2005; 79:3289–3296.

17.

Lai

, Chong

, Yeh

et al.

Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV)

J Biomed Sci, 2005; 12:711–727.

18.

Wang

, Chou

, Sakhatskyy

et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol, 2005; 79:1906–1910.

19.

Zhang

, Wang

, Li

et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol, 2004; 78:6938–6945.

20.

Guo

, Sun

, Wang

, Zhang

, Zhu

, Chen

. Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus. DNA Cell Biol, 2005; 24:510–515.

21.

Zeng

, Chow

, Hon

et al. Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem Biophys Res Commun, 2004; 315:1134–1139.

22.

Cavanagh

, Davis

, Darbyshire

, Peters

. Coronavirus IBV: Virus retaining spike glycopolypeptide S2 but not S1 is unable to induce virus-neutralizing or haemagglutination-inhibiting antibody, or induce chicken tracheal protection. J Gen Virol, 1986; 67:1435–1442.

23.

Delmas

, Rasschaert

, Godet

, Gelfi

, Laude

. Four major antigenic sites of the coronavirus transmissible gastroenteritis virus are located on the amino-terminal half of spike glycoprotein S. J Gen Virol, 1990; 71:1313–1323.

24.

Godet

, Grosclaude

, Delmas

, Laude

. Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein. J Virol, 1994; 68:8008–8016.

25.

Vautherot

, Madelaine

, Boireau

, Laporte

. Bovine coronavirus peplomer glycoproteins: Detailed antigenic analyses of S1, S2, and HE. J Gen Virol, 1992; 73:1725–1737.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.04 MB

0.00 MB

Immunogenicity and Protection Efficacy of Monomeric and Trimeric Recombinant SARS Coronavirus Spike Protein Subunit Vaccine Candidates

Abstract

Get full access to this article

References

Supplementary Material